Echo Therapeutics has announced the positive results from a clinical study of its Symphony transdermal continuous glucose monitoring system in patients with type 1 and type 2 diabetes.
The feasibility study, involving 20 adult diabetecs, was designed to assess the performance of the Symphony system in an outpatient setting at a clinical research organisation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study confirmed that Symphony successfully monitors the broad range of blood glucose values seen in people with diabetes.
The company also plans to conduct a study in critical care patients.
